Immunohistochemistry firm Biocare Medical and Hamamatsu Corporation, an innovator in imaging technologies, have announced a strategic collaboration to accelerate innovation in the rapidly expanding field of spatial biology.
Under the agreement, Biocare will co-exclusively offer Hamamatsu's MoxiePlex multi-spectral imaging system together with its own ONCORE Pro X automated staining instrument. This integrated solution delivers a seamless, end-to-end workflow from multiplex immunofluorescence and IHC staining to high-resolution digital imaging, empowering pharmaceutical and biotech companies, academic research institutions, and contract research organisations (CROs) to achieve new levels of precision and efficiency in spatial biology research and translational programmes.
"This collaboration unites Biocare's leading staining expertise with Hamamatsu's advanced digital imaging technologies to deliver a complete solution for spatial biology," said David Anderson, VP of Strategic Partnerships at Biocare. "Together, we're helping researchers generate high-quality, digital-ready data faster, accelerating discovery in cancer research and drug development."
Hamamatsu's MoxiePlex system is already being utilised in research-use-only initiatives with prominent cancer centres and CROs, supporting advancements in immuno-oncology and translational science. The agreement with Biocare strengthens Hamamatsu's presence within the IHC and spatial biology markets through Biocare's established staining platforms and global partnership network.
"Collaborating with Biocare allows us to extend the impact of MoxiePlex by pairing it with a proven staining platform that delivers superior performance in spatial biology assays," said James Butler, VP of Marketing at Hamamatsu. "We are excited to work together to deliver an integrated, scalable solution that supports scientists and clinicians to advance the promise of precision medicine."
The agreement reinforces Biocare's ongoing commitment to building a robust ecosystem of spatial biology collaborations, complementing its existing relationships with leading research and technology providers. For Hamamatsu, the collaboration accelerates adoption of its digital pathology solutions within the broader IHC and molecular research community.